Month: April 2026

First-year Targets: 20-40 Agents Live, 10-15% Efficiency Gains Axelle de Faÿ Appointed Chief Customer Experience Officer, Unifying Every Customer Touchpoint with Agentic AI Frédéric Dupont-Aldiolan Named Chief Human Resources Officer, Architecting a Workforce Augmented by AI Sidetrade (Euronext Growth: ALBFR.PA), the AI-native Order-to-Cash company, today announces two senior leadership appointments as it executes O2C Intelligence 2030, its strategic plan to operate as an AI-native enterprise. Axelle de Faÿ joins as Chief Customer Experience Officer and Frédéric Dupont-Aldiolan is appointed Chief Human Resources Officer. These appointments position the Group for an operating model where every employee works alongside AI agents. McKinsey’s State of Organizations 2026 survey finds that while 88% of organizations are now deploying AI...

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBMCAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago. Details for the Oral Presentation: Session Type/Title: Rapid Oral Abstract Session – Lung Cancer—Non-Small Cell MetastaticTitle: Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535)...

(2026-04-21) Kitron has secured an order valued at approximately EUR 37 million for the production and supply of advanced radio systems used in tactical mobile platforms. Delivery of the order is scheduled to begin in first half of 2027, and production will take place at one of Kitron’s European facilities. “Next-generation tactical communications are becoming a core pillar of modern defence programs. This contract strengthens Kitron’s trajectory in high-complexity RF systems and underlines our ability to scale with growing European and allied demand. We are proud to continue our role as a trusted test-development and manufacturing partner.” says Hans Petter Thomassen, Vice President Nordics and North America, Kitron. As defence programs expand, resilience in the electronics supply chain is becoming decisive. This contract shows how Kitron’s...

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) — LaFleur Minerals Inc. (CSE: LFLR, OTCQB: LFLRF, FSE: 3WK0) (“LaFleur Minerals” or the “Company”) is pleased to report the results from its drilling to date at the Swanson Gold Project, highlighting new gold discovery zones with the presence of broad, continuous zones of gold mineralization that extend well below the limits of the current resource model, expanding and confirming the potential for a large-scale gold system. Four (4) diamond drill holes, completed between vertical depths of approximately 300 and 450 metres and spaced over a 120-metre strike length, were specifically designed to test the down-dip continuity of the Swanson Gold Deposit. These results confirm that the new gold discovery mineralized system remains robust at depth and continues to expand beyond...

Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that the American Society of Clinical Oncology (ASCO) has accepted an abstract for presentation at the 2026 ASCO Annual Meeting, which will be held June 1-5, 2026, in Chicago, IL. “We are pleased that data from Part 1 of the MUIR trial focusing on azenosertib in combination with paclitaxel in platinum-resistant ovarian cancer (PROC) have been accepted for presentation at ASCO,” said Julie Eastland, Chief Executive Officer of Zentalis. “Paclitaxel...

May 5 at 4:30 p.m. EDTSkyworks Sets Date for Second Quarter Fiscal 2026 Earnings Release and Conference CallSkyworks Sets Date for Second Quarter Fiscal 2026 Earnings Release and Conference Call May 5 at 4:30 p.m. EDTIRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog and mixed-signal semiconductors connecting people, places and things, will host a conference call with analysts to discuss its second quarter fiscal 2026 results and business outlook on May 5, 2026, at 4:30 p.m. EDT.  After the close of the market on May 5, and prior to the conference call, Skyworks will issue a copy of the earnings press release via GlobeNewswire. The press release may also be viewed on Skyworks’ website at www.skyworksinc.com/investors. To listen to the conference...

Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced all submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA. The four oral presentations will include:Phase 1b clinical data on anzu-cel, the Company’s lead PRAME cell therapy, in advanced cutaneous and uveal melanoma with a focus on characterizing response dynamics Updated Phase 1a dose-escalation and Phase 1b dose-expansion data for the second-generation (GEN2) PRAME cell therapy candidate, IMA203CD8, in gynecologic cancers at clinically...